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We explore the possibility of incorporating historical
information, which may take the form of data from pre-
vious trials, summary information or information
derived from expert opinion into the design of phase II
clinical trials with a time-to-event endpoint.
We model the survival data by means of the Piecewise
Exponential Model and introduce a method by which a
prior baseline hazard function is derived from summary
information given by survival probabilities at given time
points. We explore the use of gamma priors for the base-
line hazard function as well as locally flat priors, where
prior opinion of parameter estimates are equal within a
given set of bounds.
We argue that placing priors on such information can
improve decision making process by increasing the preci-
sion of the main parameter of interest, the hazard ratio.
We further show that the influence of such a prior
increases as more data are attributed to the experimental
arm of a trial and argue that a prior on the baseline hazard
function to be more appropriate than priors placed on the
hazard ratio as there is typically much more information
available on this aspect of a trial.
We illustrate the methodology via a simulation study to
show how such an approach can improve measures such
as the alpha level and power of comparisons between two
therapies and make some arguments toward the case for
unequal allocations. Applications to the ViP trial currently
being run at the Liverpool Cancer Trials Unit are also
discussed.
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